Oral semaglutide for weight loss and liver fibrosis in overweight and obesity: A randomized controlled trial

What Was Tested

The paper reports a study of Semaglutide in the context of fat loss, obesity & body recomposition, published as a randomized controlled trial.

The objectives were to assess the effects of semaglutide on weight loss, non-invasive markers of liver fibrosis and cardiometabolic parameters.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Adults (≥ 18 years) with a body mass index (BMI) ≥ 30 or ≥ 27 with comorbidities (pre-diabetes, hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease) were randomized into two groups.

How the Study Was Run

The design is described as randomized and open-label.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

A randomized, open-label, controlled trial was conducted at the Asian Institute of Gastroenterology, Hyderabad, from June 2022 to December 2023.

What Was Measured

PubMed files the paper under topics including Diet, Reducing, Glucagon-Like Peptides, Liver Cirrhosis, Obesity, Overweight, Semaglutide and Weight Loss.

Author keywords: Fatty liver.

What This Means in Plain Language

The paper is a randomized and open-label study of Semaglutide in people with fat loss, obesity & body recomposition.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology), a journal based in India.

More context: the Semaglutide compound page, Fat loss, obesity & body recomposition research.